Previous 10 | Next 10 |
The company announces positive topline data from its pivotal phase III ADVOCATE trial for avacopan. More news on: ChemoCentryx, Inc., Healthcare stocks news, Stocks on the move, Read more ...
-- Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks -- -- Significantly reduced glucocorticoid toxicity -- -- Significantly improved kidney function compared to glu...
The following slide deck was published by ChemoCentryx, Inc. in conjunction with their 2019 Q3 earnings Read more ...
-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ACCOLADE Phase II Trial in C3G -- Reinforces Therapeutic Potential of Chemokine Receptor 2 (CCR2) Inhibition in the Treatment of FSGS -- MOUNTAIN VIEW, Calif., Nov. 05, 2019 (GLOBE NEWSW...
ChemoCentryx, Inc. (CCXI) Q3 2019 Earnings Conference Call November 04, 2019, 17:00 ET Company Participants Bill Slattery - IR Thomas Schall - Founder, President, CEO & Chairman Susan Kanaya - EVP, Chief Financial & Administrative Officer & Secretary Conference Ca...
Image source: The Motley Fool. ChemoCentryx Inc (NASDAQ: CCXI) Q3 2019 Earnings Call Nov 4, 2019 , 5:00 p.m. ET Operator Continue reading
ChemoCentryx, Inc. (NASDAQ: CCXI ): Q3 GAAP EPS of -$0.22 beats by $0.06 . More news on: ChemoCentryx, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
-- Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA vasculitis expected mid-to-late fourth quarter -- -- Awarded $1 million grant from the U.S. Food and Drug Administration (FDA), to support the ACCOLADE Phase II trial of avacopan in C3 Glo...
MOUNTAIN VIEW, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2019 financial results will be released after market close on Monday, November 4, 2019. ChemoCentryx executive management will host a conference call...
ChemoCentryx (NASDAQ: CCXI) develops drugs for orphan diseases, meaning those with fewer than 200,000 patients in the U.S. Currently, ChemoCentryx has four drug candidates in development with the most advanced being avacopan. This quarter, ChemoCentryx will announce pivotal trial results wit...
News, Short Squeeze, Breakout and More Instantly...
AMGEN SUCCESSFULLY COMPLETES ACQUISITION OF CHEMOCENTRYX PR Newswire TAVNEOS ® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif. , Oct. 20, ...
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS ® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17,...
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), tod...